▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #339 by analyst upside · 2026-11-12
QNRX
Quoin Pharmaceuticals, Ltd.
Healthcare · Market Cap $18M · P/E 0x
ANALYST PRICE TARGET
+441.9%
implied upside to consensus target
Current Price $3.76
Consensus Target $20.38
Bull Target $35.0
Bear Target $12.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
0
Sell
0
52-Week Low $3.25
52-Week High $23.5
YTD Return -73.3%
FUNDAMENTALS
Market Cap $18M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-5.67
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.25
52-Week High $23.5
Current Price $3.76
Bear Target $12.0
Bull Target $35.0
● Now $3.76 ● Target $20.38
TRADING DATA
Avg Volume 544K
YTD Return -73.3%
Analyst Count 8
Consensus Buy
Upside to Target +441.9%
Last Updated 2026-11-12

ANALYST SUMMARY

Quoin Pharmaceuticals, Ltd. (QNRX) is currently trading at $3.76 with a Wall Street consensus price target of $20.38, implying potential upside of 441.9% over the next 12 months. 8 analysts currently cover QNRX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $35.0, while the most cautious has a target of $12.0.

QNRX operates in the Healthcare sector with a market capitalisation of $18M. The stock is down 73.3% year-to-date and is currently trading near the lower end of its 52-week range of $3.25 – $23.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

HIND +462.6%
Vyome Holdings, Inc.
$11M · P/E 0.9x · Buy
BSEM +376.2%
BioStem Technologies, Inc.
$27M · P/E 1.2x · Buy
SPRO +422.9%
Spero Therapeutics, Inc.
$59M · P/E 7.3x · Buy
NCEL +721.4%
NewcelX Ltd.
$16M · P/E 5.6x · Hold
PBSV +210.0%
Pharma-Bio Serv, Inc.
$11M · P/E 50.0x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for QNRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity ● Initiated
Buy 2026-10-19 Building track record
BTIG ● Initiated
Buy 2026-10-12 38% win rate (8 calls)
Lake Street ● Initiated
Buy 2026-09-23 27% win rate (11 calls)
LUCID CAPITAL MARKETS ● Initiated
Buy 2026-05-04 40% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →